Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Is there any role for immunotherapy after concurrent chemoradiation in patients with mediastinal recurrence of early stage small cell lung cancer treated initially with surgery and adjuvant chemotherapy?
Related Questions
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
Is there a role for surgical debulking, local RT or subsequent line of chemotherapy for a patient with stable malignant thymoma but active myasthenia gravis?
What are your top takeaways from ESMO 2023?
Which regimen do you recommend for chemoradiation for a patient with locally advanced, inoperable thymic tumor in the setting of CKD Stage III?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
How would you treat patients with limited-stage small cell lung cancer who have short term contraindications for systemic chemotherapy?
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
Would you offer any additional adjuvant therapy after platinum based chemotherapy for patients with resected PD-L1 positive Stage II-III lung adenocarcinoma with EGFR exon 20 insertions?
How would you treat a patient with BRAF V600E-mutated metastatic lung adenocarcinoma who has progressed on chemotherapy, immunotherapy and Dabrafenib/Trametinib?
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?